Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Pamela L Kunz"'
Autor:
Pamela L Kunz, George A Fisher
Publikováno v:
Clinical and Experimental Gastroenterology, Vol 2010, Iss default, Pp 79-86 (2010)
Pamela L Kunz, George A FisherStanford University Medical Center, CA, USAAbstract: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous class of neoplasms. While surgical resection is the mainstay of treatment, non-sur
Externí odkaz:
https://doaj.org/article/37fcd187165946a6af9ee4e7fcb18eba
Autor:
Deborah A. Freedman-Cass, Tanya Fischer, Ash B. Alpert, Juno Obedin-Maliver, Pamela L. Kunz, Wui-Jin Koh, Robert W. Carlson
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:434-441
A core component of NCCN’s mission is to improve and facilitate equitable cancer care. Inclusion and representation of diverse populations are essential toward this goal of equity. Within NCCN’s professional content, inclusivity increases the lik
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53ebb048c6f9ce8705ab9339eb9d9154
https://doi.org/10.6004/jnccn.2023.7025
https://doi.org/10.6004/jnccn.2023.7025
Autor:
Rachna T. Shroff, Karyn A. Goodman, Janice M. Mehnert, Julie M. Vose, Susan E. Moran, Jennifer L. Yessaian, Lance Baldo, Brian M. Alexander, Quita B. Highsmith, Jennifer M. Mills, Pamela L. Kunz
Publikováno v:
Journal of Clinical Oncology. 41:1659-1663
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8207b6899a7eccdb0ba3e3afb22b02e7
https://doi.org/10.1200/jco.21.02219
https://doi.org/10.1200/jco.21.02219
Autor:
Pamela L. Kunz, Noah T. Graham, Paul J. Catalano, Halla S. Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew E. Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, Edmond L. Schmulbach, Diane L. Reidy-Lagunes, Jonathan R. Strosberg, Peter J. O'Dwyer, Al B. Benson
Publikováno v:
Journal of Clinical Oncology. 41:1359-1369
PURPOSE Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective responses. Retrospective and small prospective studies suggest that capecitabine and temozolomide are associated with high response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65b9ad63fed85978ca4b626804b4a887
https://doi.org/10.1200/jco.22.01013
https://doi.org/10.1200/jco.22.01013
Autor:
Stephanie L. Graff, Tanya Wildes, Narjust Duma, Don S. Dizon, Noelle K. LoConte, Edith Mitchell, Martina C. Murphy, Edith A. Perez, Sarah M. Temkin, Pamela L. Kunz, Karen M. Winkfield
Publikováno v:
Journal of Clinical Oncology. 41:1350-1358
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630472746a1cae984856ecb6b284ba25
https://doi.org/10.1200/jco.22.01060
https://doi.org/10.1200/jco.22.01060
Publikováno v:
Chest. 163:e23-e29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31ec73c4c87141ede3ee3de7102c4f56
https://doi.org/10.1016/j.chest.2022.08.2214
https://doi.org/10.1016/j.chest.2022.08.2214
Autor:
Jonathan W. Riess, Nadine S. Jahchan, Millie Das, M. Zach Koontz, Pamela L. Kunz, Heather A. Wakelee, Alan Schatzberg, Julien Sage, Joel W. Neal
Publikováno v:
Cancer Treatment and Research Communications, Vol 23, Iss , Pp 100174- (2020)
ABSTRACT: BACKGROUND: A bioinformatics approach identified antitumor effects of tricyclic antidepressants (TCAs) in small cell lung cancer (SCLC) and other high-grade neuroendocrine carcinomas (grade 3 neuroendocrine carcinomas) (G3NEC) that was subs
Externí odkaz:
https://doaj.org/article/6acd5792aa11467ab34a186b4194d15a
Autor:
Robert Lam, Nicholas Tarangelo, Rong Wang, Masayasu Horibe, Alyssa A Grimshaw, Dhanpat Jain, Samir Haffar, Fateh Bazerbachi, Pamela L Kunz, Darrick K Li
Publikováno v:
The Oncologist. 27:751-759
Background Microangiopathic hemolytic anemia (MAHA) is a rare paraneoplastic syndrome that has been reported in patients with gastric signet ring cell carcinoma (SRCC). Clinical and prognostic features of MAHA in this setting have been poorly describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164c804de7d1b28ba9e3994db2bfda54
https://doi.org/10.1093/oncolo/oyac093
https://doi.org/10.1093/oncolo/oyac093
Autor:
Arnaud Demange, Hugo Duarte, Jonathan R. Strosberg, Andrew Eugene Hendifar, James C. Yao, Philippe Ruszniewski, Germo Gericke, Marianne Pavel, Martyn Caplin, Eric P. Krenning, Sakir Mutevelic, Edward M. Wolin, Mariani Maurizio F, Erik Mittra, Pamela L. Kunz, Enrique Grande, Ettore Seregni, Lisa Bodei, Amy Bartalotta, Eric Van Cutsem
Publikováno v:
The Lancet Oncology, 22(12), 1752-1763. Lancet Publishing Group
Summary Background The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0058dd366f1b523fe4859adad415c3
https://doi.org/10.1016/s1470-2045(21)00572-6
https://doi.org/10.1016/s1470-2045(21)00572-6
Autor:
Dermot O’Toole, Pamela L. Kunz, Susan M. Webb, Grace Goldstein, Sheila Khawaja, Mark McDonnell, Sandra Boiziau, Delphine Gueguen, Aude Houchard, Antonio Ribeiro-Oliveira, Ally Prebtani
Publikováno v:
Advances in therapy.
Real-world data evaluating patients' injection experiences using the latest devices/formulations of the long-acting (LA) somatostatin analogs (SSAs) lanreotide Autogel/Depot (LAN; Somatuline®) and octreotide LA release (OCT; Sandostatin®) are limit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3da4b42eef6612ff91693b39566e46a1
https://pubmed.ncbi.nlm.nih.gov/36502449
https://pubmed.ncbi.nlm.nih.gov/36502449